TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00973544

Intervention type: OTHER
Intervention: Cultures taken from the drain discharge
Description: Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.

Intervention type: OTHER
Intervention: Cultures taken from the drain discharge
Description: Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
Study: NCT01727648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT in sequential combination with dCIT
Description: The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distributed Constraint-Induced Therapy
Description: The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
Study: NCT03567278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE TA™
Description: ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
Study: NCT01662388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Separation ring
Description: Separation ring placed along with automatrix band

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: automatrix band
Description: band placed with a tightening device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automatrix band
Description: band placed with a tightening device
Study: NCT01097811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: 250 mg orally q.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin
Description: 1 g orally q.i.d.
Study: NCT02022670

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic sodium nitrite capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: 80 mg/d or 160 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: 80 mg/d or 160 mg/d
Study: NCT03552276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG18_07 I (Tildrakizumab 200 mg)
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG18_07 I (Tildrakizumab 200 mg)
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG18_07 I (Tildrakizumab 200 mg)
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG18_07 I (Tildrakizumab 200 mg)
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG18_07 II (Tildrakizumab 100 mg)
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG18_07 II (Tildrakizumab 100 mg)
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG18_07 II (Tildrakizumab 100 mg)
Description: injection
Study: NCT03999372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyaluronan binding system
Description: Hyaluronan binding system for sperm selection for ICSI procedures (PICSI)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: Normal ICSI procedure
Study: NCT02406092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab SC 1400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per standard local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per standard local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered as per standard local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as per standard local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as per standard local practice.
Study: NCT01449760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Balance Board
Description: These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
Study: NCT02506270

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airseal Trocar
Description: 28 patients are treated with the AirSeal insufflation and trocar system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: conventional trocar
Description: 28 patients are treated with a conventional insufflation and trocar system
Study: NCT04366024

Intervention type: OTHER
Intervention: other
Description: clinical diagnosis
Study: NCT03214172

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15/20 mg
Study: NCT02540031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional oral preparation (3L of PEG+Asc, Coolprep®)
Description: The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral preparation (2L of PEG+Asc, Coolprep®)
Description: The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
Study: NCT02025504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColoWrap
Description: ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ColoWrap
Description: ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
Study: NCT01727648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Therapy
Description: Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose-matched control therapy
Description: Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
Study: NCT00945061

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intracavitary balloon brachytherapy
Description: Patients undergo brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiation therapy
Description: Patients undergo radiotherapy
Study: NCT05576168

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: overexpression STRA6/miRNA3
Description: RBP4 express in patients with T2DM or not

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: overexpression STRA6/miRNA3
Description: RBP4 express in patients with T2DM or not
Study: NCT02864186

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Women wont use support bra 24 hours a days for six months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: surgical support bra
Description: Women will use surgical support bra 24 hours a day for six months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: common support bra
Description: Women will use common support bra 24 hours a day for six months
Study: NCT03584997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ABB And Autogenous Particulate
Description: Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF, ABB & Autogenous Particulate
Description: adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
Study: NCT03429985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRRM Intervention
Description: Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development and life trajectories of adolescent males.
Study: NCT01259648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 µg/kg remifentanil
Description: 0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 µg/kg remifentanil
Description: 1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
Study: NCT01083979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomes
Description: Intravesical instillation
Study: NCT03263130

Intervention type: OTHER
Intervention: As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap
Study: NCT04011826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Trial nasal mask (F&P)
Description: This trial nasal mask will serve as the participant's primary PAP/BPAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial nasal mask as their primary PAP/BPAP therapy mask for 6 months after Visit 3.
Study: NCT02138305

Intervention type: DEVICE
Group type: OTHER
Intervention: ComboMap XT Guidewire
Description: Intracoronary pressure and flow measurements

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 'SPY' NIRF During CABG
Description: FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
Study: NCT04308434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-11
Description: Flavor variant CSD190601-11 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-12
Description: Flavor variant CSD190601-12 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-13
Description: Flavor variant CSD190601-13 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-14
Description: Flavor variant CSD190601-14 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-15
Description: Flavor variant CSD190601-15 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-16
Description: Flavor variant CSD190601-16 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-17
Description: Flavor variant CSD190601-17 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-21
Description: Flavor variant CSD190601-21 of a 3.0% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-22
Description: Flavor variant CSD190601-22 of a 3.0% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-23
Description: Flavor variant CSD190601-23 of a 3.0% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-24
Description: Flavor variant CSD190601-24 of a 3.0% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-25
Description: Flavor variant CSD190601-25 of a 3.0% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-26
Description: Flavor variant CSD190601-26 of a 3.0% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-27
Description: Flavor variant CSD190601-27 of a 3.0% nicotine ENDS product
Study: NCT02916641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Study: NCT04308460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrocentesis
Description: lavage of the temporomandibular joint was done

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative arthroscopy
Description: operative intervention inside the temporomandibular joint was done using arthroscope
Study: NCT03262571

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: Duretic therapy is then optimized according to the presence and severity of B-lines in group A.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Lung ultrasound
Description: Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
Study: NCT03404531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Messages Intervention Group
Description: The Social Media Messages Intervention Group will receive theoretically-grounded messages through social media in order to encourage participants to regularly access the newly developed, culturally-tailored website that includes information about treatment as prevention and pre-exposure prophylaxis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Website Only Group
Description: The Website Only group will have access to the newly developed, culturally-tailored website but will not receive social media messages.
Study: NCT05300230

Intervention type: DEVICE
Intervention: Neuro Zti cochlear implant and Neuro 2 sound processor
Description: The study will consist in 3 visits:~* Visit 1: it will be carried out the first contact and learning the measurement procedure.~* Visit 2: it will be evaluated the speech perception and the measurement of the pupil dilatation in silence and noise conditions.~* Visit 3: it will be analysed the effect of the change in the cochlear implant programming parameters.
Study: NCT02708849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Study: NCT01443897

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo capsule
Description: 0 IU vitamin D2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mushrooms
Description: untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mushrooms
Description: untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UVB-treated mushrooms, 400 IU vitamin D2
Description: UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UVB-treated mushrooms, 1,000 IU vitamin D2
Description: UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
Study: NCT01948050

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non-invasive transcranial direct current stimulation (tDCS)
Study: NCT02008669

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: A blood sample will be taken from each patient and the following parameters will be assessed : magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.

Intervention type: OTHER
Intervention: Gustatory sensitivity test using Taste strips
Description: 16 Taste Strips impregnated with 4 flavors (sweet, sour, salty, bitter, each flavor present at 4 different concentrations), are offered to the patient one after the other in a so-called pseudorandomized sequence. The task of the patient is to choose one of the following answers: sweet / sour / salty / bitter / no taste.~Each correct answer is granted one point. In addition to the impregnated strips, two tasteless strips can be integrated in the examination at any point of time (no point)

Intervention type: OTHER
Intervention: Questionnaires
Description: Evaluation of the following parameters by validated questionnaires (name of the questionnaire in bracket):~* Fatigue (EMIF-SEP)~* Dysphagia (DYMUS)~* Food intake (semi-structured questionnaire)~* Depression (BDI-II)~* Daily energy expenditure (NAP)~* Visual analog scale to study quality of sleep
Study: NCT01411566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills trainig for patients with dual diagnosis
Description: Skills trainig for patients with dual diagnosis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: regular treatment
Description: regular treatment
Study: NCT01203943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-930
Description: CC-930 50 mg PO daily up to 56 weeks beginning on Day 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-930
Description: CC-930 100 mg PO daily up to 56 weeks beginning on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-930
Description: C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
Study: NCT03930940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric autocontrol device with cuffs placed on arm and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 4 to 5 times.

Intervention type: OTHER
Group type: OTHER
Intervention: Regular treatment
Description: Regular treatment is based on associated guidelines for ICH.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular treatment
Description: Regular treatment is based on associated guidelines for ICH.
Study: NCT01233934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine 1% Gel
Description: Small amount applied over the lesion twice a day for 7 days.
Study: NCT02708849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dose placebo
Study: NCT00644930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the application of NPPV
Description: ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated. BIPAP Vision machine (Respironics, PA, USA) were used for NPPV.
Study: NCT03575117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common-Sense Model (CSM) Be Well
Description: Theoretically informed text messages and images that cover how physical activity is linked to decreasing colorectal cancer risk.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACS usual messages
Description: Information distributed by the American Cancer Society as information on the link between physical activity and cancer risk (source: www.cancer.org)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NCI HealthyYouTXT--Get Active (HYT--GA)
Description: Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.
Study: NCT01233934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine 1% Cream
Description: Small amount applied over the lesion twice a day for 7 days.
Study: NCT00154115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosimendan
Description: Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT02715518

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI using 2nd generation drug-eluting stent
Description: Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.~1. FFR-guided strategy arm~2. Angiography-guided strategy arm
Study: NCT03575117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NCI HealthyYouTXT--Get Active (HYT--GA)
Description: Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.